Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trialJean‐Michel Molina, Juergen Rockstroh, Johan Lombaard et al.|The Lancet HIV|2018Cited by 145
Rapid Development of an Integrated Network Infrastructure to Conduct Phase 3 COVID-19 Vaccine TrialsAlfredo J Mena Lora, Catherine Orrel, Jessica E. Long et al.|JAMA Network Open|2023Cited by 38